The distribution of hepatitis C virus genotypes in patients with hepatocellular carcinoma
Background: Hepatic cirrhosis develops within 20-30 years in approximately 20% of individuals chronically infected with hepatitis C virus (HCV). Aims and Objective: This study aimed to determine the distribution of HCV genotypes in patients with HCV ...
Ayfer Bakır +4 more
doaj +1 more source
Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes +3 more
wiley +1 more source
Prevalence of Hepatitis C Virus Genotypes in Mashhad, North-east Iran [PDF]
Background: Hepatitis C is a disease with significant global impact. The distribution of hepatitis C virus (HCV) genotypes in Mashhad (the Northeast and the biggest city after the capital of Iran) is unknown.
H Nomani +10 more
doaj +2 more sources
Objectives:Hepatitis C virus (HCV) is an important viral agent of hepatitis, cirrhosis and hepatocellular carcinoma. In our study, we aimed to determine the HCV genotype distribution among patients with HCV who presented to our hospital in a city in the ...
Uğur TÜZÜNER +4 more
doaj +1 more source
The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. [PDF]
OBJECTIVE:We aimed to evaluate the correct assignment of HCV genotype/subtypes 1a and 1b by cobas® HCV genotyping (GT) assay (Roche Molecular Diagnostics) compared with nonstructural protein 5B (NS5B) sequencing.
J A Fernández-Caballero +4 more
doaj +1 more source
Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. [PDF]
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action ...
Bidell, Monique R +4 more
core +2 more sources
CYP3A5*3, CYP3A4*1B and MDR1 C3435T Genotype Distributions in Ecuadorians [PDF]
Polymorphisms in CYP3A genes, such as CYP3A5 and CYP3A4, as well as in the MDR1 gene, which encodes for P‐glycoprotein, have been implicated as genetic markers in several disorders. Differences in the frequency distribution of the allelic variants CYP3A5*3, CYP3A4*1B, and MDR1 3435T have been demonstrated between distinct ethnic groups.
Sinués, Blanca +6 more
openaire +2 more sources
Crosstalk between the ribosome quality control‐associated E3 ubiquitin ligases LTN1 and RNF10
Loss of the E3 ligase LTN1, the ubiquitin‐like modifier UFM1, or the deubiquitinating enzyme UFSP2 disrupts endoplasmic reticulum–ribosome quality control (ER‐RQC), a pathway that removes stalled ribosomes and faulty proteins. This disruption may trigger a compensatory response to ER‐RQC defects, including increased expression of the E3 ligase RNF10 ...
Yuxi Huang +8 more
wiley +1 more source
Hepatitis C virus genotype and its correlation with viral load in patients from Kathmandu, Nepal
Introduction: Knowledge about the distribution of hepatitis C virus (HCV) genotype and its correlation with viral load are important for the decision of treatment and the prediction of disease progression, however such information is very limited in ...
Bhavesh Kumar Mishra +5 more
doaj +1 more source
Function‐driven design of a surrogate interleukin‐2 receptor ligand
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang +9 more
wiley +1 more source

